Live price temporarily unavailable.
Armata Pharmaceuticals (ARMP) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$23.4M | −$16.2M | −$17.7M | −$19.8M | −$21.6M | −$23.8M | −$36.9M | −$40.9M | −$42.4M | −$36.6M |
| Net income | −$18.8M | −$12.8M | −$16.7M | −$19.5M | −$22.2M | −$23.2M | −$36.9M | −$69.0M | −$18.9M | −$173.8M |
| EPS (diluted) | −$148.02 | −$13.08 | −$3.59 | −$2.55 | −$1.35 | −$0.96 | −$1.08 | −$1.91 | −$0.89 | −$4.80 |
| Balance sheet | ||||||||||
| Cash and equivalents | $5.13M | $5.13M | $9.66M | $6.03M | $9.65M | $10.3M | $14.9M | $13.5M | $9.29M | $8.69M |
| Total assets | $18.2M | $11.1M | $14.5M | $25.5M | $39.5M | $69.8M | $95.8M | $98.4M | $86.4M | $76.9M |
| Total liabilities | $8.43M | $3.41M | $6.85M | $10.9M | $20.7M | $44.4M | $59.8M | $130.4M | $134.5M | $295.5M |
| Shareholders' equity | $9.72M | — | $7.69M | $14.6M | $18.9M | $25.4M | $36.1M | −$32.1M | −$48.0M | −$218.6M |
| Cash flow | ||||||||||
| Operating cash flow | −$10.6M | −$9.19M | −$10.6M | −$15.6M | −$18.3M | −$23.6M | −$32.5M | −$47.4M | −$37.6M | −$25.8M |
| Capital expenditure | $279.0K | $58.0K | $875.0K | $224.0K | $824.0K | $1.30M | $2.21M | $8.14M | $1.88M | $542.0K |
| Free cash flow | −$10.9M | −$9.25M | −$11.5M | −$15.8M | −$19.1M | −$24.9M | −$34.7M | −$55.6M | −$39.4M | −$26.3M |
| Dividends paid | $80.0K | — | — | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$9.76M | −$10.5M | −$8.19M | −$6.84M | −$7.78M | −$13.8M | −$8.79M | −$10.3M |
| Net income | −$5.48M | $2.60M | −$6.53M | −$16.3M | −$26.7M | −$124.3M | −$115.3M | $74.1M |
| EPS (diluted) | −$0.15 | $0.20 | −$0.20 | −$0.45 | −$0.74 | −$3.41 | −$3.16 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $17.1M | $9.29M | $11.7M | $4.33M | $14.8M | $8.69M | $4.75M | $24.0M |
| Total assets | $98.2M | $86.4M | $87.3M | $80.8M | $89.5M | $76.9M | $69.8M | $90.0M |
| Total liabilities | $149.2M | $134.5M | $141.0M | $150.3M | $185.1M | $295.5M | $381.4M | $321.1M |
| Shareholders' equity | −$51.0M | −$48.0M | −$53.8M | −$69.5M | −$95.6M | −$218.6M | −$311.6M | −$231.2M |
| Cash flow | ||||||||
| Operating cash flow | −$8.86M | −$7.93M | −$7.58M | −$7.21M | −$4.30M | −$6.67M | −$5.78M | −$8.67M |
| Capital expenditure | $340.0K | −$77.0K | $99.0K | $149.0K | $242.0K | $52.0K | $63.0K | $17.0K |
| Free cash flow | −$9.20M | −$7.85M | −$7.68M | −$7.36M | −$4.54M | −$6.73M | −$5.84M | −$8.68M |
From Armata Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Armata Pharmaceuticals in our feed yet.